Samsung Biologics Co Ltd operates within the Biological products exc. diagnostic sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Samsung Biologics Co Ltd with three other
pharmaceutical manufacturers in Asia:
Jinyu Bio-Technology Co Ltd
sales of 1.52 billion Chinese Renmimbi [US$235.41 million]
of which 95%
Tonghua Dongbao Medicines Company Limited
(2.03 billion Chinese Renmimbi [US$315.00 million]
of which 96%
was Pharmaceutical), and
Hualan Biological Engineering Inc
based in China
(1.93 billion Chinese Renmimbi [US$300.15 million]
of which 94%
was Blood Product).